Research and Development Trend of China Blood Products Industry, 2013

Published: Jun, 2013 | Pages: 88 | Publisher: Huidian Research
Industry: Healthcare | Report Format: Electronic (PDF)

At present, the demand in China's blood products market is strong, but restricts by blood plasma supply and NDRC price limit, China's blood products market has been developing steadily since 2005; in recent three years, this industry has maintained the growth rate of about 20%. Huidian Research estimated that the scale of China's blood products market was CNY 17.28 billion in 2012.

The per capita blood products consumption of Chinese residents is extremely low, and there is a relatively large gap compares with the developed countries. China's albumin supply has been tight, and the annual growth rate will be about 15% in the future. The per capita consumption of human immunoglobulin for intravenous injection is only 10% of the foreign countries, since 2004, the growth rate in this aspect has been maintaining at the level of more than 30%; at present, this application in small and medium-scale hospitals is still unpopular, and the development potential is relatively huge; as for the sales of coagulation factor products, China is still in its infancy, compares with foreign market share of 40%, China owns a broad market space. 

Due to the shortage of blood plasma source, China's blood products have been in short supply in recent years. Although the lot release volume of blood products in China has been increasing in recent years, the continuous economic growth, population aging trend and the changing of medication habits have determined the continuous increase of blood products demands, and the status of blood plasma shortage is difficult to change in the short term, which determines that China's blood products will be in short supply for a quite long period of time. In this situation, the consumers almost have no bargaining power, and the industry's profitability is strong; therefore, China's blood products industry will continue to keep high prosperity in the future. 

The concentration ratio of international blood products is very high, which is in oligopoly and determined by market demand; the relationship between supply and demand is balance, the market growth mainly depends on the introduction of new products and new adaptation diseases. However, China's blood products are in the independent and closed state, and the industry is in the state of short supply. The industry is affected by policies and guided by government; the enterprises are relatively scattered but tend to concentrate. In a longer period in the future, the competitiveness of blood products enterprises will be determined by the ownership of blood plasma resources and comprehensive utilization of blood plasma. 

"Research and Development Trend of China Blood Products Industry, 2013" firstly conducts a brief introduction of the global blood products development; and then, this report deeply analyzes the development of this industry in China, and the contents involve market scale, supply and demand, price, competitive landscape, industry policies and industry barriers; what's more, this report also conducts specific analysis on China's blood plasma resources, blood products market segments and key enterprises; finally, this report conducts a professional analysis on the development trend of China's blood products industry, which can provide  decision-making references for the investors.

 1. Overview of Blood Products Industry 
1.1 Definition 
1.2 Classification 
1.3 Business Model 

2. Overview of Global Blood Products Development 
2.1 Overview 
2.2 Market Capacity 
2.3 Sales Structure 
2.4 Market Outlook

3. Overview of China's Blood Products Industry 
3.1 Market Scale 
3.1.1 Overall Gap between China and Foreign Countries 
3.1.2 Scale of Domestic Market 
3.2 Market Supply and Demand 
3.3 Market Price 
3.4 Competitive Landscape 
3.4.1 Competitive Pressure from Foreign Enterprises is not Huge
3.4.2 Competitiveness of Blood Products Enterprises Will be Determined by the Ownership of Blood Plasma Resources in the Next Period of Time
3.4.3 As for Long-term Perspective, the Competitiveness of Blood Products Enterprises Will be Determined by Blood Plasma Comprehensive Utilization and R&D and Marketing Ability
3.4.4 Competition of Domestic Blood Products Enterprises
3.5 Industry Supervision System and Main Industry Policies
3.5.1 Industry Competent Department
3.5.2 Main Laws and Regulations 
3.5.3 Main Industry Policies
3.6 Industry Barriers
3.6.1 Policy Barrier
3.6.2 Resource Barrier 
3.6.3 Barrier of Technology and Quality Control Ability 
3.7 Operation Overview of Key Enterprises 
3.7.1 Development Overview 
3.7.2 Comparison between China and Foreign Countries as for the Profitability Structure of Key Blood Products Enterprises 

4. Specific Analysis of Domestic Blood Plasma Resources 
4.1 Blood Plasma Collection 
4.2 The Blood Plasma Collection Volume Increases Year by Year 
4.3 Domestic Blood Plasma Station Resources 
4.4 Blood Plasma Volume Forecast of China's Blood Products 

5. Analysis of China's Blood Products Market Segment 
5.1 Human Albumin 
5.1.1 Market Supply and Demand 
5.1.2 Development Prospect 
5.2 Immune Globulin 
5.2.1 Market Demand 
5.2.2 Market Supply 
5.3 Coagulation Factors
5.3.1 Market Demand 
5.3.2 Market Supply

6. Main Manufacturers in China 
6.1 Hualan Biological Engineering, Inc.
6.1.1 Company Profile 
6.1.2 Operation State 
6.1.3 Revenue Composition 
6.1.4 Clients and Suppliers 
6.1.5 Research and Development State
6.1.7 Core Competitiveness 
6.1.8 Development Strategy and Business Plan in 2013
6.2 Shanghai RAAS Blood Products Co., Ltd. 
6.2.1 Company Profile 
6.2.2 Main Business 
6.2.3 Clients and Suppliers 
6.2.4 Research and Development State 
6.2.5 Core Competitiveness 
6.2.6 Development Strategy and Business Plan in 2013
6.3 Beijing Tiantan Biological Products Co., Ltd. 
6.3.1 Company Profile 
6.3.2 Operation State 
6.3.3 Revenue Composition 
6.3.4 Clients and Suppliers 
6.3.5 Core Competitiveness 
6.3.6 Business Plan in 2013
6.4 China Biologic Products, Inc. 
6.4.1 Company Profile 
6.4.2 Main Products 
6.4.3 Revenue Composition
6.5 Jiangxi Boya Biological Pharmaceutical Co., Ltd. 
6.5.1 Company Profile 
6.5.2 Main Products 
6.5.3 Main Business 
6.5.4 Clients and Suppliers 
6.5.5 Business Plan in 2013

7. Future Development Analysis of Blood Products Industry 
7.1 Development Trend 
7.1.1 Blood Plasma Station Resource is the Most Important Competitiveness 
7.1.2 Trend of Concentrated Monopoly 
7.1.3 Isolation Technology 
7.1.4 Industry Expansion and Transformation 
7.1.5 Leading Edge New Products 
7.2 Opportunities and Challenges in Blood Products Industry 
7.2.1 Opportunities 
7.2.2 Challenges 
7.2.3 Bottleneck of the Industry Development and Suggestions